- ICH GCP
- 米国臨床試験登録
- 臨床試験 NCT07207408
- オリジナルトライアル
18〜55歳の成人におけるRF1V-1018ワクチンの免疫原性、安全性、および忍容性
第2相、18〜55歳の成人におけるRF1V-1018ワクチンの免疫原性、安全性、および忍容性に関するランダム化、多施設試験
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
調査の概要
状態
詳細な説明
This dose-finding study will evaluate the immunogenicity, safety, and tolerability of multiple doses and regimens of rF1V-1018 vaccine in healthy adults. Immunogenicity blood samples will be drawn at several timepoints during the study. Participants will return to the clinic for periodic visits for study specific evaluations including evaluation of immunogenicity and safety. Safety assessments will be done at regular intervals through the end of the trial.
Six dose regimens will be tested in Part 1 of the study. Up to two dose regimens from Part 1 will be chosen for Part 2 of the study.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Florida
-
Miami、Florida、アメリカ、33172
- 103
-
-
Kansas
-
El Dorado、Kansas、アメリカ、67042
- AMR- El Dorado
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、889119
- AMR- Las Vegas
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45212
- CTI Clinical Research Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults 18 to 55 years of age
- Healthy participants or participants with stable pre-existing medical conditions Pre-existing stable medical condition means a participant who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.
- Able to comply with the protocol schedule and procedures
- Able and willing to provide written informed consent
- If female of child-bearing potential and heterosexually active, has practiced adequate contraception for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through three months following the final trial injection
A premenopausal woman who has at least one of the following is considered not of childbearing potential:
- Documented hysterectomy
- Documented bilateral salpingectomy
- Documented bilateral oophorectomy
- Documented and current bilateral tubal ligation or occlusion
Exclusion Criteria:
-
A history of plague disease or have previously received any plague vaccine
-
Active tuberculosis or other systemic infectious process
-
History of human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
-
History of autoimmune disorder
-
History of sensitivity to any component of trial vaccines
-
Body mass index ≥ 30 kg/m2
-
Has received the following prior to any trial injection:
a) ≤ 14 days: i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG) b) ≤ 28 days: i) Any live vaccine ii) Any investigational medicinal agent c) ≤ 90 days: i) Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first trial vaccine administration or planned administration during the trial period. (For corticosteroids, this will mean prednisone ≥20 mg/day, or equivalent). Inhaled, topical, and intraarticular steroids are allowed.
ii) Granulocyte or granulocyte-macrophage colony stimulating factor iii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by-case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor) iv) Antisense oligonucleotides v) Drugs/investigational agents with very long half-lives (defined as ≥ 60 days) (eg, radioactive iodine, amiodarone, liraglutide, nirsevimab, teplizumab, evinacumab, and obinutuzumab) vi) Infusion of blood products d) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells
-
If female is pregnant (known before or established at the time of screening), breastfeeding, or planning breastfeeding or a pregnancy
-
Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
-
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
-
Oral temperature ≥ 38°C (≥ 100.4°F) at the time of vaccine administration
-
History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD)
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1 Arm 1
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
実験的:Part 1 Arm 2
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
実験的:Part 1 Arm 5
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
実験的:Part 1 Arm 6
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
実験的:Part 1 and Part 2: Arm 3
This Part 1 arm was selected for Part 2. |
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
実験的:Part 1 and Part 2: Arm 4
This Part 1 arm was selected for Part 2. |
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
抗RF1V抗体レベル
時間枠:最終研究ワクチン接種から4週間後
|
最終研究ワクチン接種から4週間後
|
|
|
Evaluate safety of rF1V-1018
時間枠:injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
|
Evaluate adverse events |
injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- DV2-DC02-02
- VCG26632 (その他の識別子:Sanofi)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。